ClinVar Miner

Submissions for variant NM_007294.3(BRCA1):c.2696T>G (p.Val899Gly) (rs1064794483)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000481820 SCV000569292 uncertain significance not provided 2016-08-16 criteria provided, single submitter clinical testing This variant is denoted BRCA1 c.2696T>G at the cDNA level, p.Val899Gly (V899G) at the protein level, and results in the change of a Valine to a Glycine (GTC>GGC). Using alternate nomenclature, this variant would be defined as BRCA1 2815T>G. This variant has not, to our knowledge, been published in the literature as pathogenic or benign. BRCA1 Val899Gly was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Valine and Glycine share similar properties, this is considered a conservative amino acid substitution. BRCA1 Val899Gly occurs at a position that is not conserved and is located in DNA binding domain as well as the RAD51 binding domain (Chen 1998, Narod 2004). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether BRCA1 Val899Gly is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.